Related Experiment Videos
Impact of co-amoxiclav on polymorphonuclear granulocytes from chronic hemodialysis patients
A M Cuffini1, V Tullio, F Giacchino
1Department of Public Health and Microbiology, University of Turin, Turin, Italy. annamaria.cuffini@unito.it
Abstract:
Phagocyte-dependent host defenses are frequently impaired in maintenance hemodialysis patients who show an increased susceptibility to infections. In these individuals, the course of infections can be more aggressive than in normal hosts, and the antibiotic of choice should have a high antimicrobial effect without impairing host defenses. Hence, in uremic patients, the antibiotic enhancement of phagocyte functions may be of potential clinical importance in the outcome of bacterial infections. Because we demonstrated previously that co-amoxiclav had beneficial properties that result in enhancement of the microbicidal functions of human polymorphonuclear cells (PMNs) from healthy subjects, we investigated the influence of this combination on the activities of PMNs from chronic hemodialysis patients against Klebsiella pneumoniae, a human pathogen that can pose severe problems in patients whose immunity is impaired. PMNs from chronic dialysis patients showed a diminished in vitro phagocytic efficiency with a reduced phagocytosis and bactericidal activity towards intracellular K. pneumoniae compared with that seen in PMNs from healthy subjects. When co-amoxiclav was added to PMNs from chronic hemodialysis patients, it was able to restore the depressed primary functions of PMNs, resulting in a significant high increase in both phagocytosis or killing activity. A similar pattern was detected with PMNs collected from hemodialysis patients treated with co-amoxiclav. The results of the present study provide evidence that co-amoxiclav is able to induce stimulation of depressed phagocytic response of PMNs from patients on chronic hemodialysis, restoring their primary functions both in vitro and in vivo.
Insights
Co-amoxiclav enhances phagocyte function in hemodialysis patients, improving their ability to fight Klebsiella pneumoniae infections. This antibiotic combination restores depressed immune cell activity, crucial for combating infections in vulnerable patients.
Area of Science:
- Immunology
- Infectious Diseases
- Nephrology
Background:
- Maintenance hemodialysis patients exhibit impaired phagocyte-dependent host defenses, increasing infection susceptibility.
- Infections in these patients can be severe, necessitating antibiotics that enhance, not hinder, host defenses.
- Co-amoxiclav previously showed beneficial effects on phagocyte functions in healthy individuals.
Purpose of the Study:
- To investigate the effect of co-amoxiclav on polymorphonuclear cell (PMN) activity in chronic hemodialysis patients against Klebsiella pneumoniae.
- To determine if co-amoxiclav can restore depressed phagocytic and bactericidal functions in PMNs from hemodialysis patients.
Main Methods:
- In vitro assessment of phagocytic efficiency and bactericidal activity of PMNs from chronic dialysis patients against K. pneumoniae.
- Addition of co-amoxiclav to PMNs from hemodialysis patients to evaluate functional restoration.
- Analysis of PMNs collected from hemodialysis patients undergoing co-amoxiclav treatment.
Main Results:
- PMNs from chronic dialysis patients demonstrated reduced phagocytosis and bactericidal activity against K. pneumoniae compared to healthy controls.
- Co-amoxiclav significantly increased phagocytosis and killing activity of PMNs from hemodialysis patients in vitro.
- Similar functional restoration was observed in PMNs from patients treated with co-amoxiclav in vivo.
Conclusions:
- Co-amoxiclav effectively stimulates depressed phagocytic responses in PMNs from patients on chronic hemodialysis.
- This antibiotic combination restores essential PMN functions, offering potential clinical benefits for infection outcomes in hemodialysis patients.
- Co-amoxiclav demonstrates both in vitro and in vivo efficacy in enhancing host defense mechanisms in this vulnerable population.